- Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, Study of Neoadjuvant Chemotherapy alone versus Neoadjuvant Chemotherapy plus Nivolumab or Nivolumab and BMS- 986205, Followed by Continued Post- Surgery Therapy with Nivolumab or Nivolumab and BMS-986205 in Participants with Muscle-Invasive Bladder Cancer
This study is looking at new ways to treat bladder cancer that has grown into the muscle. It compares standard chemotherapy with chemotherapy plus new immunotherapy drugs (like Nivolumab) before and after surgery, to see which approach works best and is safest.
For: Bladder Cancer Muscle-Invasive Bladder CancerGermany · Norway · France - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 1b/2a Three-Part Open-Label Multicenter Study to Evaluate the Safety and Efficacy of LY2880070 as Monotherapy and in Combination with Gemcitabine in Patients with Advanced or Metastatic Cancer with a Focus on Ovarian Cancer
This study is testing a new medicine, LY2880070, alone or with another cancer drug, gemcitabine. It's for women with advanced or metastatic cancer, especially ovarian cancer. We want to see how safe the new medicine is and if it helps control the cancer.
For: Advanced or Metastatic CancerPoland · Croatia - AuthorisedTherapeutic confirmatory (Phase III)
Toripalimab plus chemotherapy as first-line treatment for recurrent and/or metastatic nasopharyngeal cancer: safety and activity in non-endemic population
This study is testing a new combination of treatments, including a drug called toripalimab, for a type of cancer called nasopharyngeal cancer that has come back or spread. Doctors want to see if this new treatment is safe and works well for people outside of areas where the cancer is common.
For: Recurrent Metastatic Nasopharingeal CarcinomaItaly